How iPS cells changed the world

The burst of reprogramming technology in recent years has revolutionized the field of stem cell biology, offering new opportunities for personalized, regenerative therapies. The direct reprogramming of somatic cells to induced pluripotent stem cells (iPSCs) has provided an invaluable tool to study and model a wide range of human diseases. Here, we review the transforming potential of such a strategy in research and in therapies applicable to the hematology field.

show abstract

“…Indeed, strong support from pharmaceutical industries and governments will be needed to move forward with iPSC-based therapies [64]. …”

Section: Discussionmentioning

confidence: 99%

Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases

Cascino

Ummarino

et al. 2017

Cells

View full text Add to dashboard Cite

show abstract

“…Takahashi had claimed to stop the degeneration process and the patient experienced an improvement in vision [126]. The trial was halted due to unexplained mutations observed by Yamanaka in the transplanted RPE and the patients' iPS [126,127]. This trial proved that several safety assays need to be established to validate preclinical studies before they are safe to begin future clinical trials.…”

Section: Discussionmentioning

confidence: 99%

“…The swift journey from skin to eyes started in September 2014, when ophthalmologist Masayo Takahashi collaborated with the stem cell pioneer Shinya Yamanaka and transplanted RPE (retinal pigment epithelium) sheets generated from patients iPS cells into the right eye of the female suffering from age related macular degeneration. Takahashi had claimed to stop the degeneration process and the patient experienced an improvement in vision [126]. The trial was halted due to unexplained mutations observed by Yamanaka in the transplanted RPE and the patients' iPS [126,127].…”

Section: Discussionmentioning

confidence: 99%

Ips Progression a Decade Devoted

K¹

2017

J Cell Sci Ther

View full text Add to dashboard Cite

Yamanaka and Takahashi's astonishing discovery in 2006 revolutionized the world of stem cells. Simplicity and reproducibility of IPSC's cells opened doors for extensive therapeutic advancements and potential clinical trials particularly in the field of Regenerative medicine. In 2012, nobel prize was presented to both researchers for the breakthrough in reprogramming somatic cells to a pluripotent state with the expression of "Yamanakas cocktail" of OKSM quartet transcription factors: sex determining region y box2 (sox2), octamer binding transcription factor4 (oct4), krupple like factor (klf4) and myelocymatosis oncogene (c-myc). Rationale of iPS use is attributed to its unlimited cell source circumventing ethical hindrance. This comprehensive review will summarize mechanisms of IPS production and cell therapy applications. Moreover, appreciate the improvements and initiatives in iPS technology, scrutinize the scientific claim of indistinguishable resemblance of iPS and eSC, evaluate the constraints during iPS manipulation and analyze safety of these pluripotent cells in clinical scenarios.

show abstract

“…To date, only one human trial using iPSCs has been reported; this key study used the cells to treat macular degeneration. This same trial has was halted because of the presence of two non-tumorigenic genetic changes found in the patient specific iPSCs and the differentiated Retinal Pigment Epithelium sheets generated [4]. Nonetheless, one can imagine the plethora of clinical trials that will emerge in the near future and their vast potential to impact how we ameliorate human disease.…”

Section: The Future Of Pbmc Derived Ipscsmentioning

confidence: 99%

“…One year later, the same laboratory, as well as an independent research team, both reported successfully reprogramming human adult cells into iPSCs [2,3]. This magnum opus stirred a whirlwind of scientific research activity in the stem cell field over the past 10 years, yielding vast advances in basic research and disease modelling and hinting at potential applications in the clinical and therapeutic arenas (Figure 1) [4]. …”

Section: Introductionmentioning

confidence: 99%

Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead

Hokayem¹,

Cukier²,

Dykxhoorn³

2016

J Alzheimers Dis Parkinsonism

View full text Add to dashboard Cite

Since the creation of induced Pluripotent Stem Cells (iPSCs) ten years ago, hundreds of publications have demonstrated their considerable impact on disease modeling and therapy. In this commentary, we will summarize key milestones, benefits and challenges in the iPSC field. Furthermore, we will highlight blood as an effective and easily accessible source for patient-specific iPSCs derivation in the context of work done in our laboratory and others.

show abstract

How iPS cells changed the world

Cited by 120 publications

References 14 publications

Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases

Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases

Ips Progression a Decade Devoted

Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead

Contact Info

Product

Resources

About